Demonstrated Technological Superiority Amidst Strengthening Regulations

Roche has obtained additional label expansion approval under the European Union's (EU) In Vitro Diagnostic Regulation (IVDR) for its immunohistochemistry (IHC)-based companion diagnostic platform, the 'VENTANA MMR RxDx Panel.' This signifies that Roche has solidified its leading position in the precision medicine diagnostics market by overcoming increasingly stringent European regulatory hurdles. The VENTANA panel diagnoses a patient's eligibility for immune-oncology therapy by assessing the expression of MLH1, PMS2, MSH2, and MSH6, which are DNA mismatch repair (MMR) proteins in tumors. This approval demonstrates Roche's exceptional responsiveness and technological capabilities in navigating challenging regulatory standards.

Maximizing the Immune-Oncology Portfolio

With this expanded European label, the range of therapies and indications that can be used in conjunction with the VENTANA panel has significantly increased. In addition to the previously approved indications of endometrial cancer and colorectal cancer, it can now be used to select patients with microsatellite instability-high (dMMR) solid tumors for treatment with Keytruda (pembrolizumab), an immune checkpoint inhibitor from Merck & Co., for gastric cancer, small intestinal cancer, and biliary tract cancer. Furthermore, it can be used to select patients who will receive Imfinzi (durvalumab) monotherapy or Lynparza (olaparib) combination therapy from AstraZeneca, as well as Jemperli (dostarlimab) from GSK.

A Leap Towards Standardizing Precision Medicine

The label expansion of the diagnostic platform represents a critical turning point in providing optimal, personalized precision medicine to cancer patients in clinical practice. Previously, different diagnostic methods had to be used depending on the cancer type or treatment. Now, a single, standardized platform, the VENTANA panel, enables rapid and consistent treatment decisions. In particular, dMMR status is a critical biomarker for predicting the response to immune checkpoint inhibitors, making this indication expansion clinically significant in providing new treatment opportunities for patients.

Securing Leadership in the Companion Diagnostics Market

In 2026, the global companion diagnostics (CDx) market is estimated to be worth approximately $9.8 billion to $11.5 billion, and it is rapidly growing along with the demand for precision medicine. Roche Diagnostics, with sales of 13.8 billion Swiss francs (CHF) in 2025, is the undisputed leader, and this label expansion has further solidified its market dominance. In particular, it has widened the market share gap with competing platforms such as Agilent's 'MMR IHC Panel pharmDx,' creating a solid barrier to entry. Roche's integrated business, which includes both diagnostics and therapeutics, is a powerful asset in forging global partnerships.

Digital Innovation in Future Precision Medicine

Building on this European approval, Roche is pushing for global expansion of approvals and leading digital innovation through the integration of artificial intelligence (AI). In April 2025, it received Breakthrough Device Designation from the U.S. FDA for its AI-based companion diagnostic device, 'VENTANA TROP2 RxDx,' for lung cancer, demonstrating its leadership in future diagnostics. This device will be used to select patients for datopotamab deruxtecan (Datopotamab Deruxtecan, brand name Datopotamab Deruxtecan), an antibody-drug conjugate (ADC) from AstraZeneca and Daiichi Sankyo. Roche's approach, which combines regulatory capabilities and innovative technologies, will become a core infrastructure for the next generation of precision oncology.